{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:33Z","timestamp":1740107433013,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00280-021-04377-0","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T22:02:56Z","timestamp":1638396176000},"page":"271-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7149","authenticated-orcid":false,"given":"Stefanie D.","family":"Krens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasja F.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"1","key":"4377_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","volume":"119","author":"M Friedlander","year":"2010","unstructured":"Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM et al (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119(1):32\u201337","journal-title":"Gynecol Oncol"},{"issue":"3","key":"4377_CR2","doi-asserted-by":"publisher","first-page":"114.e9","DOI":"10.1016\/j.urolonc.2016.10.023","volume":"35","author":"A Sidana","year":"2017","unstructured":"Sidana A, Kadakia M, Friend JC, Krane LS, Su D, Merino MJ et al (2017) Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. Urol Oncol 35(3):114.e9-e14","journal-title":"Urol Oncol"},{"issue":"1","key":"4377_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","volume":"120","author":"C Hodge","year":"2019","unstructured":"Hodge C, Badgwell BD (2019) Palliation of malignant ascites. J Surg Oncol 120(1):67\u201373","journal-title":"J Surg Oncol"},{"issue":"9","key":"4377_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/modpathol.2009.88","volume":"22","author":"G-X Tong","year":"2009","unstructured":"Tong G-X, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM et al (2009) Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol 22(9):1218\u20131227","journal-title":"Mod Pathol"},{"issue":"6","key":"4377_CR5","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00280-019-03952-w","volume":"84","author":"FJE Lubberman","year":"2019","unstructured":"Lubberman FJE, Benoist GE, Gerritsen W, Burger DM, Mehra N, Hamberg P et al (2019) A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. Cancer Chemother Pharmacol 84(6):1179\u20131185","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4377_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D et al (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111(10):1909\u20131916","journal-title":"Br J Cancer"},{"issue":"2","key":"4377_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357\u2013371","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4377_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10637-015-0304-9","volume":"34","author":"DC Imbs","year":"2016","unstructured":"Imbs DC, Paludetto MN, N\u00e9grier S, Powell H, Lafont T, White-Koning M et al (2016) Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. Invest New Drugs 34(1):41\u201348","journal-title":"Invest New Drugs"},{"key":"4377_CR9","unstructured":"FDA. Sutent Clinical Pharmacology and Biopharmaceutics Review 2006 [cited 2020 11\/10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021938_S000_Sutent_BioPharmR.pdf"},{"key":"4377_CR10","unstructured":"EMA. Votrient CHMP assessment report 2010. Available from:\n https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/votrient-epar-public-assessment-report_en.pdf. Accessed   1 Dec 2021"},{"issue":"3","key":"4377_CR11","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","volume":"37","author":"N Zhan","year":"2016","unstructured":"Zhan N, Dong WG, Wang J (2016) The clinical significance of vascular endothelial growth factor in malignant ascites. Tumour Biol 37(3):3719\u20133725","journal-title":"Tumour Biol"},{"issue":"4","key":"4377_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11523-014-0306-0","volume":"9","author":"SF Mulder","year":"2014","unstructured":"Mulder SF, Boers-Sonderen MJ, van der Heijden HF, Vissers KC, Punt CJ, van Herpen CM (2014) A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Target Oncol 9(4):331\u2013338","journal-title":"Target Oncol"},{"key":"4377_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1311024","author":"FJE Lubberman","year":"2017","unstructured":"Lubberman FJE, van Erp NP, Ter Heine R, van Herpen CML (2017) Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. Acta Oncol. https:\/\/doi.org\/10.1080\/0284186X.2017.1311024","journal-title":"Acta Oncol"},{"issue":"2","key":"4377_CR14","first-page":"45","volume":"64","author":"J Mori","year":"2018","unstructured":"Mori J, Nakayama Y, Hiragino T, Matsuyama H (2018) Successful treatment of peritoneal dissemination recurrence with axitinib in papillary renal cell carcinoma: a case report. Hinyokika Kiyo 64(2):45\u201348","journal-title":"Hinyokika Kiyo"},{"issue":"4","key":"4377_CR15","doi-asserted-by":"publisher","first-page":"205427041558508","DOI":"10.1177\/2054270415585087","volume":"6","author":"E Jennison","year":"2015","unstructured":"Jennison E, Wathuge GW, Gorard DA (2015) Renal cell carcinoma presenting with malignant ascites. JRSM Open 6(4):2054270415585087","journal-title":"JRSM Open"},{"issue":"4","key":"4377_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s13691-012-0039-9","volume":"1","author":"A Yao","year":"2012","unstructured":"Yao A, Iwamoto H, Morizane S, Isoyama T, Sejima T, Takenaka A (2012) A case of advanced renal cell carcinoma with peritoneal carcinomatosis responding to sorafenib therapy. Int Cancer Conf J 1(4):198\u2013200","journal-title":"Int Cancer Conf J"},{"issue":"6","key":"4377_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T et al (2013) PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19(6):1363\u20131374","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4377_CR18","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00262-020-02621-9","volume":"69","author":"JJ Wang","year":"2020","unstructured":"Wang JJ, Siu MK, Jiang YX, Chan DW, Cheung AN, Ngan HY et al (2020) Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression. Cancer Immunol Immunother 69(11):2275\u20132289","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04377-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04377-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T17:39:40Z","timestamp":1643737180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04377-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4377"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04377-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mentioned relationships are outside of the submitted work and invoiced by the institution. SFM has received honoraria from Pfizer, Roche, Merck Sharp and Dohme and Bristol Meyers Squibb. NPvE had received research grants from Novartis, Astellas, Janssen-Cilag, Pfizer, Ipsen, has been on an advisory board for Pfizer, and received honoraria from Bayer and Sanofi. SDK declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}